John Edward Porter, a long-time key Congressional appropriator and advocate for biomedical research, received the Research!America Legacy Award at an advocacy awards dinner March 14.
Fifteen years ago, when Ethan Basch started developing measures for aggregating patient-reported outcomes, many of his colleagues in oncology saw no promise in this enterprise.
FDA has approved a supplemental Biologics License Application updating the Opdivo (nivolumab) dosing schedule to include 480 mg infused every four weeks for a majority of approved indications.
Roche's acquisition of Flatiron Health signals the pharmaceutical industry's interest in using real-world data to measure value, said Brigham Hyde, CEO and founder of Precision Health AI, a company that uses artificial intelligence to define cancer datasets for precision oncology.
Roche's purchase of Flatiron Health will accelerate the development of real-world data suitable for supporting regulatory decisions, said Daniel O'Day, CEO of Roche Pharmaceuticals.
The affiliation between UT Health San Antonio Cancer Center and MD Anderson Cancer Center became active on Feb. 20. “Administratively, the two institutions are distinct. Patients will be cared for by the physicians and nurses of the [San Antonio] Mays Cancer Center, but certainly the platform of the care that they're being provided has been heavily informed and integrated with MD Anderson, based on their treatment templates and methodology,” Ruben Mesa, director of the Mays Cancer Center, said to The Cancer Letter.
“The notion that cancer's not one disease, but thousands of diseases is really starting to sink in, and the implications of that fact are being felt throughout [NCI], and it means we have to change how we do everything. I hope that the early days of the Sharpless administration will be remembered as a time when we really bought into that reality and did some things differently,” NCI Director Norman “Ned” Sharpless said in a conversation with The Cancer Letter.
Withholding e-cigarettes as an alternative from smokers who are unable to quit equals supporting the continued use of conventional cigarettes, said David Abrams, a member of the National Tobacco Reform Initiative.
Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.
Gary Reedy has a big turnaround project on his hands.
